Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka - LARVOL DELTA

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - P2 | N=92 | Completed | Sponsor: National Health Research Institutes, Taiwan | Active, not recruiting ➔ Completed

Trial completion • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Efficacy of Switching to Levetiracetam After S-1-Induced Phenytoin Concentration Increase: A Case Report. (PubMed, Cureus) - "He had experienced generalized tonic-clonic seizures 48 years prior and had been taking PHT (170 mg/day) and carbamazepine (250 mg/day)...The findings of this case report suggest an approach for switching from PHT to another antiepileptic drug when PHT levels increase due to interactions with S-1. Switching to LEV may result in fewer interactions."

Journal • CNS Disorders • Epilepsy • Gastric Cancer • Oncology • Oral Cancer • Solid Tumor

Safety, efficacy, and pharmacokinetics (PK) of TS-1 combined with cisplatin in advanced cancer patients with severe hepatic dysfunction. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT03519074 The abstract will be released to the public on May 22, 2025 at 4:00 PM"

Clinical • Metastases • PK/PD data • Hepatology • Liver Failure • Oncology

Phase II trial of transarterial chemoembolization followed by sintilimab (anti-PD-1), oxaliplatin, and S-1 combined with either trastuzumab (HER-2 positive) or apatinib (HER-2 negative) as first-line therapy for gastric cancer with liver metastases. (ASCO 2025) - P2 | "Clinical Trial Registration Number: ChiCTR2200057726 The abstract will be released to the public on May 22, 2025 at 4:00 PM"

Clinical • P2 data • Gastric Cancer • Oncology • Solid Tumor • HER-2

Five-year survival outcomes from CRES3T: S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor. (ASCO 2025) - "Clinical Trial Registration Number: s031180401 The abstract will be released to the public on May 22, 2025 at 4:00 PM"

Surgery • Oncology

Prognostic impacts of biological and conditional factors in patients with anatomically resectable pancreatic adenocarcinoma treated with preoperative chemoradiotherapy. (PubMed, Medicine (Baltimore)) - "This retrospective study included 109 R-PDAC patients treated with gemcitabine- or S-1 plus gemcitabine-based preoperative CRT from February 2005 to April 2023...Biological factors, including serum levels of CA19-9 and CEA, along with conditional factor of Eastern Cooperative Oncology Group performance status ≥1, were identified as independent prognostic factors for R-PDAC patients treated with preoperative CRT. Preoperative CRT is considered effective for cases lacking these risk factors."

Journal • Observational data • Retrospective data • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CA 19-9 • CEACAM5

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer (clinicaltrials.gov) - P3 | N=416 | Recruiting | Sponsor: Sunshine Lake Pharma Co., Ltd. | Trial completion date: Nov 2023 ➔ Dec 2026 | Trial primary completion date: Aug 2023 ➔ Aug 2026

Trial completion date • Trial primary completion date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • EGFR

Efficacy and safety of camrelizumab in combination with S-1 plus oxaliplatin sequenced by camrelizumab-based maintenance therapy as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: a retrospective cohort study. (PubMed, J Gastrointest Oncol) - "Thus, it might serve as a first-line standard-of-care treatment for such patients. However, prospective randomized studies should be carried out to confirm the findings."

Journal • Retrospective data • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

Immunochemotherapy and nab-paclitaxel intraperitoneal infusion for advanced gastric cancer with malignant ascites (IGCC 2025) - P2 | "Patients will receive sintilimab combined with S-1/oxaliplatin and intraperitoneal nab-paclitaxel (100 mg/m²) as first-line treatment, with treatment cycles repeated every 3 week... As of Nov 30, 2024, a total of 33 patients were enrolled in the study. The median PFS was 5.7 months. The median OS was 10.0 months."

Metastases • Anemia • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Hematological Disorders • Oncology • Solid Tumor

Transarterial oxaliplatin plus S-1, sintilimab as neoadjuvant therapy in locally advanced G/GEJ cancer:early results. (IGCC 2025) - P3 | "The present results indicate that transarterial oxaliplatin plus S-1 and sintilimab as neoadjuvant therapy is effective and has a manageable safety profile in locally advanced G/GEJ cancer. ClinicalTrials.gov registration: NCT05593458."

Clinical • Metastases • Gastric Cancer • Gastroesophageal Cancer • Oncology

Nanoparticle albumin-bound paclitaxel, S-1 and sintilimab as adjuvant therapy in stage IIIC GC (IGCC 2025) - "The RD of Nab-PTX as adjuvant chemotherapy was 100 mg/m2. Dragon-VII demonstrated good tolerance and encouraging antitumor activity of the combination of Nab-PTX, S-1 and sintilimab as adjuvant therapy in patients with stage IIIC GC."

Clinical • Hematological Disorders • Leukopenia • Neutropenia • Oncology

Predictive Value of 18F-FDG PET in Assessing Treatment Response to Neoadjuvant Chemotherapy for Gastric Cancer (IGCC 2025) - "Aims: This study aimed to assess the potential of 18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) as a predictive tool for treatment response to the S-1+Oxaliplatin (SOX) regimen... FDG-PET appears to be a valuable tool for predicting treatment response to neoadjuvant SOX therapy in gastric cancer. Determining the optimal ΔSUVmax threshold could improve the accuracy of histological tumor response predictions."

Clinical • FDG PET • Gastric Cancer • Oncology • Solid Tumor

Neoadjuvant immunotherapy in Patients(Including Elderly and Bleeding) with Locally Advanced Gastric Cancer: FRIENDSHIP-GC-01 Trial (IGCC 2025) - "All of the patients received neoadjuvant therapy (Envafolimab 300 mg Q3W + SOX (S-1 40mg, Oxaliplatin 130 mg/m2)Q3W )for 3 cycle, followed by surgery, adjuvant therapy (Envafolimab 300 mg Q3W + SOX (S-1 40mg, Oxaliplatin 130 mg/m2)Q3W)for 3-5 cycle...The other aim was to assess organoid,PCT,ctDNA mutations and transcript levels ( RNA-Seq, mRNA) in relation to patient outcome and prognosis to determine which patients are more likely to benefit from immune-combination chemotherapy. We have completed the enrollment of 29 cases, of which 11 patients underwent radical surgery, 4 patients had pCR, and the proportion of pCR reached 36.4%."

Clinical • IO biomarker • Metastases • Gastric Adenocarcinoma • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Oncology • Solid Tumor • PD-L1

High loss of subcutaneous adipose tissue during neoadjuvant chemotherapy predicts poor prognosis in gastric cancer (IGCC 2025) - P=N/A | "Methodology: This was a secondary analysis of a phase 3, open-label, multicenter, randomized clinical trial (NCT01364376), assessing the safety and efficacy of S-1 plus oxaliplatin (SOX) vs fluorouracil, leucovorin, and oxaliplatin (FOLFOX) as a perioperative chemotherapy regimen for patients with locally advanced GC... High loss of SAT during NAC is prognostic of reduced survival in patients with GC. Assessing and monitoring body composition can effectively guide individual nutrition intervention and the prevention of complications."

Clinical • Gastric Cancer • Hematological Disorders • Oncology • Sarcopenia • Solid Tumor

Adjuvant gp96 immunotherapy plus SOX chemotherapy after gastrectomy: A randomized controlled trial (IGCC 2025) - "This trial is to investigate the safety and efficacy of autologous heat shock protein gp96 combined oxaliplatin plus S-1 (SOX) for gastric cancer patients in adjuvant settings... Postoperative adjuvant autologous gp96 immunotherapy with SOX chemotherapy shows survival benefit with acceptable adverse events."

Clinical • Gastric Cancer • Oncology • Solid Tumor

Gastrectomy after response to intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. (IGCC 2025) - " We evaluated the safety and efficacy of surgery in 3 clinical trials of combination chemotherapy regimens; S-1/paclitaxel (PTX)+ IP PTX, S-1/oxaliplatin+ IP PTX, capecitabine/cisplatin+ IP docetaxel... Gastrectomy for after response to IP plus systemic chemotherapy is safe and could achieve more prolonged survival."

Gastric Cancer • Oncology • Peritoneal Cancer • Solid Tumor

Cadonilimab plus chemotherapy as neoadjuvant treatment for locally advanced gastric/gastroesophageal junction cancer (IGCC 2025) - "Methodology: In this ongoing, single-arm, phase 2 study, 37 patients with locally advanced G/GEJ adenocarcinomas (cT3-4a N+ M0, CY0, P0) will be enrolled and treated with 3 cycles of SOX (oxaliplatin 130mg/m2, IV, d1; S-1 40-60 mg, PO, bid, d1-d14; q21d) plus cadonilimab (10mg/Kg IV, d1, q21d), followed by radical D2 gastrectomy... Encouraging pCR rate and manageable safety suggested that cadonilimab plus SOX chemotherapy may provided a new neoadjuvant treatment option for patients with locally advanced gastric cancer."

Clinical • Metastases • Anemia • Dermatitis • Dermatology • Endocrine Disorders • Esophageal Cancer • Fatigue • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Hematological Disorders • Immunology • Leukopenia • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia • CTLA4

Normothermic intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases: 20-year experience in Japan (IGCC 2025) - "We have developed a multidisciplinary treatment with systemic chemotherapy and intraperitoneal (IP) paclitaxel (PTX) or docetaxel (DOC) combined with gastrectomy after response to chemotherapy. We performed phase I and II trials of five regimens: S-1/PTX plus IP PTX, S-1/oxaliplatin plus IP PTX, S-1/cisplatin plus IP PTX, capecitabine/cisplatin plus IP DOC, and FOLFOX plus IP PTX... Multidisciplinary treatment with long-term normothermic IP and systemic chemotherapy is safe and effective for gastric cancer with peritoneal metastasis."

Gastric Cancer • Oncology • Solid Tumor

Intraperitoneal+intravenous vs. intravenous paclitaxel+S-1 in gastric cancer with peritoneal metastasis: Results from DRAGON-01 trial (IGCC 2025) - "Intraperitoneal and intravenous paclitaxel plus S-1 significantly improved overall survival in gastric cancer patients with peritoneal metastasis, with manageable toxicity."

Gastric Adenocarcinoma • Gastric Cancer • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Solid Tumor

Clinical and pathological characteristics and treatment of gastric cancer during pregnancy. (PubMed, Indian J Cancer) - "Pregnancy-associated gastric cancers are usually of poor differentiation and high malignancy and may present without specific clinical symptoms. CEA and CA19-9 can be used to assist the diagnosis of gastric cancer during pregnancy. Gestational age, pathological type, stage, and patient's wishes should be considered in planning treatment to maximize the benefits of mother and fetus."

Journal • Retrospective data • Gastric Cancer • Oncology • Pain • Solid Tumor • CA 19-9 • CEACAM5 • HER-2

Immune checkpoint inhibitors plus chemotherapy in the first-line treatment of young unresectable gastric cancer patients: a multicentre real-world study. (PubMed, Front Oncol) - "After screening, 134 patients were included for analysis: 63 received dual chemotherapy (mFOLFOX6, XELOX, SOX and two-drug containing paclitaxel), 32 PD-1 inhibitors plus dual chemotherapy (mFOLFOX6, XELOX, SOX and two-drug containing paclitaxel), and 39 triple regimens (two-drug chemotherapy combined with apatinib or trastuzumab, or triple chemotherapy based on platinum, fluorouracil and paclitaxel)...Young patients with GC have unique clinical characteristics and are not sensitive to immunotherapy. Triple regimens, especially intraperitoneal infusion of paclitaxel followed by intravenous paclitaxel combined with S-1 and apatinib oral therapy, deserve to be studied as first-line therapies."

Checkpoint inhibition • IO biomarker • Journal • Real-world evidence • Gastric Cancer • Oncology • Solid Tumor • HER-2 • PD-L1

A Rare Case of Radical Resection for the Synchronous Double Cancer of Primary Pancreatic Squamous Cell Carcinoma and Primary HER2-Positive Gastric Cancer after Multidisciplinary Treatment (PubMed, Gan To Kagaku Ryoho) - "Trastuzumab plus capecitabine and oxaliplatin, followed trastuzumab plus S-1 and oxaliplatin(SOX), was employed for gastric cancer...Finally, trastuzumab plus SOX was employed for gastric cancer, and 60 Gy of radiotherapy followed nab-paclitaxel and gemcitabine(GA)was employed for pancreatic cancer...Histopathological findings revealed pancreatic squamous cell carcinoma, ypT3N0M0, and pathological response is Grade 2, also gastric cancer, ypT3 N0M0, and pathological response is Grade 2a. Adjuvant chemotherapy with S-1 was administered and is still ongoing."

Journal • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • HER-2

Torsion of Metastatic Ovarian Tumor Originating From Sigmoid Colon Cancer. (PubMed, Cureus) - "The patient began chemotherapy with tegafur, gimeracil, oteracil potassium, oxaliplatin, and bevacizumab, resulting in a decrease in carbohydrate antigen 19-9 levels, though carcinoembryonic antigen levels increased. Despite bevacizumab treatment, the patient's postoperative course was uneventful, and she was discharged on day 12. Chemotherapy was resumed. In patients with metastatic ovarian tumors who present with sudden abdominal pain, ovarian torsion should be considered in the differential diagnosis, even in the context of malignancy."

Journal • Colon Cancer • Colorectal Cancer • Hematological Disorders • Oncology • Ovarian Cancer • Pain • Respiratory Diseases • Solid Tumor • CEACAM5

Predictive value of baseline CT imaging features combined with serum biomarkers for neoadjuvant chemotherapy response in adenocarcinoma of the gastroesophageal junction. (PubMed, Am J Cancer Res) - "Baseline CT characteristics, when combined with serum markers, effectively predict NAC response in GEJ adenocarcinoma."

Biomarker • Journal • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • AFP • CA724 • CEACAM5

Chronopharmacokinetic model analysis of 5-fluorouracil following S-1 administration in rats: comparison with infusion and other prodrugs for chronochemotherapy. (PubMed, J Pharm Sci) - "Chronopharmacokinetic analysis revealed minimal circadian variation in 5-fluorouracil clearance with S-1 (amplitude-to-mesor ratio: ±14.6%) compared to long-term 5-fluorouracil infusion (±28.0%) and other oral prodrugs including capecitabine (±43.0%) and uracil-tegafur (±36.7%), which showed pronounced fluctuations. These results suggest that S-1 provides consistent 5-fluorouracil exposure regardless of dosing time, offering a practical advantage by simplifying treatment schedules and reducing the need for chronomodulated therapy. This study could advance the development of 5-fluorouracil-based chronochemotherapy using oral prodrug regimens, enabling more personalized and effective cancer treatment strategies."

Journal • PK/PD data • Preclinical • Colorectal Cancer • Oncology • Solid Tumor